IHCL, la empresa matriz de Taj, llegará pronto a los 400 hoteles gracias a la demanda de viajes deportivos y religiosos
IHCL is experiencing rapid expansion, nearing 400 hotels, with a goal of 700 hotels and 70,000 rooms by 2030.
The company is investing heavily in sports, event-driven, and religious tourism, alongside strategic moves into airport hotel markets.
IHCL reported strong financial results with a 19% profit increase year over year, despite international disruptions and geopolitical tensions.
Summary
Indian Hotels Company Limited (IHCL) is rapidly expanding its hotel portfolio, expecting to surpass 400 hotels this month and aiming for 700 by 2030 as part of its 'Accelerate 2030' strategy. The company is targeting growth through investments in sports, religious, and event-driven tourism, as well as strategic acquisitions, including airport hotels and a key new property in Frankfurt. Despite facing international travel disruptions and regional tensions, IHCL posted robust financial growth in the first quarter, driven by diversified offerings and operational efficiencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth
The global cell and gene therapy supply chain software market is set to expand from USD 0.27 billion in 2025 to USD 1.32 billion by 2035, at a CAGR of 15.2%. Driven by demand for advanced therapies, the market is enhanced by cloud-based technologies and key players like Azenta Life Sciences and Lonza. Cell and Gene Therapy Supply Chain Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to offering. The global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in 2025, to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, to 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies. The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems. Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users. The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023. Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years. Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future. The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including process component, type of software, mode of deployment, scale of operation and key geographical regions. Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as type of software, key features, application area, mode of deployment, scale of operation, regulatory guidelines followed and type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and most active players based on the number of software solutions offered. Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as developer strength and product portfolio strength. Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on company overviews, software solutions portfolio, financial information, recent developments and an informed future outlook. Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings. Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements. Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain. Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs. Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth. Sample Players in the Cell and Gene Therapy Supply Chain Software Market, Profiled in the Report Include: Azenta Life Sciences Biocair BioLife Solutions CareDx Cryoport Lonza NMDP BioTherapies TraceLink TrakCel Veeva Systems Emerson LabVantage Solutions Marken MasterControl QuickSTAT Siemens Stafa Cellular Therapy Steiner STEMSOFT Software TECHNIDATA Thermo Fisher Scientific KEY QUESTIONS ANSWERED IN THIS REPORT How many companies are currently engaged in this market? Which are the leading companies in this market? What kind of partnership models are commonly adopted by industry stakeholders? What are the factors that are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. ADDITIONAL BENEFITS Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell and Gene Therapy Supply Chain CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
CNET
20 minutes ago
- CNET
Mortgage Rates Dip Down: Mortgage Rates on July 28, 2025
Check out CNET Money's weekly mortgage rate forecast for a more in-depth look at what's next for Fed rate cuts, labor data and inflation. The average for a 30-year fixed mortgage is 6.77% today, a decrease of -0.04% since one week ago. The average rate for a 15-year fixed mortgage is 5.96%, which is a decrease of -0.07% compared to a week ago. To secure a lower mortgage interest rate, consider increasing your down payment, improving your credit score or purchasing mortgage points. What's behind high rates these days? Concerns about persistent inflation, threats of a global trade war and policy turbulence have created an uncertain economic outlook. In response, the Federal Reserve has adopted a wait-and-see approach and left interest rates unchanged this year. Financial markets largely expect the Fed to resume lowering rates in September, particularly if President Trump eases some of his aggressive tariff measures or if the labor market continues to deteriorate. Prospective homebuyers shouldn't expect mortgage rates to become affordable overnight. While cheaper borrowing costs gradually trickle down to the housing market, the Fed doesn't directly set lenders' mortgage rates. In today's unaffordable housing market, mortgage rates are just one piece of the puzzle. High home prices and skyrocketing homeownership expenses, like insurance and property taxes, are further compounding the pressure on prospective buyers. The possibility of a job-loss recession is also pushing many households to tighten their budgets and take on less financial risk. When mortgage rates start to fall, be ready to take advantage. Experts recommend shopping around and comparing multiple offers to get the lowest rate. Enter your information here to get a custom quote from one of CNET's partner lenders. About these rates: Bankrate's tool features rates from partner lenders that you can use when comparing multiple mortgage rates. What's behind today's high mortgage rates? The average 30-year fixed rate has hovered just below 7% for the last several months, resulting in cost-prohibitive monthly payments. Mortgage rates primarily take their cues from the 10-year Treasury yield, which reflects investors' collective expectations regarding inflation, labor market health, upcoming monetary policy shifts and the impact of global factors like tariffs. If investors anticipate persistently high inflation or significant government borrowing, they'll demand higher returns on their bonds, which in turn keeps mortgage rates elevated. "Rates could fall if inflation keeps cooling and the labor market softens," said Jeb Smith, licensed real estate agent and member of CNET Money's expert review board. "On the other hand, tariffs could create new inflation pressure. Add in government deficits and increased bond supply, and that puts upward pressure on rates." Even as the Fed eventually starts to reduce borrowing rates, experts caution that significant market volatility is likely. As a result, homebuyers are adopting a more patient and strategic approach to financing, comparing various loan types and planning ahead. "Some are waiting, others are getting pre-approved now so they're ready to act if rates fall," said Smith. For a look at mortgage rate movement in recent years, see the chart below. Mortgage rate forecast for 2025 While the housing market was expected to rebound in 2025, it has remained stagnant due to ongoing economic and political uncertainties. Median family income has not kept pace with the surge in housing costs, requiring many households to earn double or triple their salary to afford a modest home in some cities. Mortgage rates would have to drop significantly, close to 6% or below, to drum up significant homebuying demand. According to Smith, though, the more likely scenario is that interest rates will take modest and gradual steps down over the coming months. A return to the record-low rates, around 2-3%, we saw during the pandemic would only happen if the economy tipped into a severe recession. Fannie Mae now predicts rates around 6.5% by the end of 2025 and 6.1% by the end of 2026. Ongoing uncertainty could cause rates to stay high, or increase further. For instance, if tariffs cause inflation to reignite, which most experts and Fed officials expect, it could result in higher bond yields and fewer interest rate cuts by the central bank. Both would be bad for mortgage rates. What is a good mortgage type and term? Each mortgage has a loan term, or payment schedule. The most common mortgage terms are 15 and 30 years, although 10-, 20- and 40-year mortgages also exist. With a fixed-rate mortgage, the interest rate is set for the duration of the loan, offering stability. With an adjustable-rate mortgage, the interest rate is only fixed for a certain amount of time (commonly five, seven or 10 years), after which the rate adjusts annually based on the market. Fixed-rate mortgages are a better option if you plan to live in a home in the long term, but adjustable-rate mortgages may offer lower interest rates upfront. 30-year fixed-rate mortgages The average interest rate for a standard 30-year fixed mortgage is 6.77% today. A 30-year fixed mortgage is the most common loan term. It will often have a higher interest rate than a 15-year mortgage, but you'll have a lower monthly payment. 15-year fixed-rate mortgages Today, the average rate for a 15-year, fixed mortgage is 5.96%. Though you'll have a bigger monthly payment than a 30-year fixed mortgage, a 15-year loan usually comes with a lower interest rate, allowing you to pay less interest in the long run and pay off your mortgage sooner. 5/1 adjustable-rate mortgages A 5/1 adjustable-rate mortgage has an average rate of 6.03% today. You'll typically get a lower introductory interest rate with a 5/1 ARM in the first five years of the mortgage. But you could pay more after that period, depending on how the rate adjusts annually. If you plan to sell or refinance your house within five years, an ARM could be a good option. Calculate your monthly mortgage payment Getting a mortgage should always depend on your financial situation and long-term goals. The most important thing is to make a budget and try to stay within your means. CNET's mortgage calculator below can help homebuyers prepare for monthly mortgage payments. Where can I find the best mortgage rates? Though mortgage rates and home prices are high, the housing market won't be unaffordable forever. It's always a good time to save for a down payment and improve your credit score to help you secure a competitive mortgage rate when the time is right. Save for a bigger down payment: Though a 20% down payment isn't required, a larger upfront payment means taking out a smaller mortgage, which will help you save in interest. Boost your credit score: You can qualify for a conventional mortgage with a 620 credit score, but a higher score of at least 740 will get you better rates. Pay off debt: Experts recommend a debt-to-income ratio of 36% or less to help you qualify for the best rates. Not carrying other debt will put you in a better position to handle your monthly payments. Research loans and assistance: Government-sponsored loans have more flexible borrowing requirements than conventional loans. Some government-sponsored or private programs can also help with your down payment and closing costs. Shop around for lenders: Researching and comparing multiple loan offers from different lenders can help you secure the lowest mortgage rate for your situation.
Bloomberg
21 minutes ago
- Bloomberg
Lots of Structural Growth Opportunities Beyond US: Niven (Video)
00:00 How are you interpreting this 15%? Is this a positive or a negative for Europe? Well, thank you very much for having me. And what a day to be on after all of the news of the weekend and all the news coming through overnight. I think for us, this is a headline that ultimately papers over structural issues. So we're seeing a lot of the trade deficits, a lot of the kind of fiscal issues within the US not be touched by this headline. So this is a headline we think that really goes some way towards bringing that certainty thus far to the markets. And you see those reactions coming through this morning. But what we're not seeing is that long term predictability of what this ultimately means. We need to see the US think about it as productivity. That's where you've seen that slow growth and we need to think about how it re-powers that reshoring it needs to see. So we're seeing these these kind of relief rallies, but ultimately we would say there's more that needs to be done, more that needs to be tackled within the US unless we continue to see the weakening dollar that we seen here today. Well, bring that right by here to Europe and how that translates to some of these European names. We've we're now six months, seven months into the year. And one of the big questions has been whether this momentum or at least fund flow from the US into Europe has legs or is this a short term tactical rotation? Which is it? So we see a lot of structural growth opportunities beyond the US. So we're seeing a lot of these interesting trends in energy, in healthcare. So that's partly why it's lovely to see those healthcare bounce today. But we're seeing, you know, non-U.S. structural sustainable growth opportunities emerging. And I think that's what we're going to start seeing. Beyond the headlines, this is all about more global, more industrial, more kind of em-link growth opportunities. And I would love to see the kind of the the EU begin to invest behind those opportunities going into the next decade and beyond. Stephanie, given your portfolio manager and now we've had this new news, if it seems like that pharma, autos, these kind of names are being included in these in these carve outs, there's no longer maybe the threat of sectoral tariffs. Have you changed your portfolio in any way over the last five sessions? No. I mean, we invest with long term structural trends and we see healthcare as one of those. And it's been great to see that kind of pulse returning within the life sciences space. We're seeing some of the tools names come out and say, actually, we're beginning to be past the bottom. So these are areas that were quite hard to hit coming out of COVID and actually seeing that vital signs kind of elevating, improving. It's been fantastic to kind of see come through into the market. So, no, we're not adjusting. We're investing for the long term.
